Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$1.57B |
| 2 |
Tesla
TSLA
|
+$1.06B |
| 3 |
Amazon
AMZN
|
+$597M |
| 4 |
Qualcomm
QCOM
|
+$374M |
| 5 |
AbbVie
ABBV
|
+$373M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$1.54B |
| 2 |
Johnson & Johnson
JNJ
|
+$561M |
| 3 |
UnitedHealth
UNH
|
+$353M |
| 4 |
Meta Platforms (Facebook)
META
|
+$345M |
| 5 |
Starbucks
SBUX
|
+$340M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 21.21% |
| 2 | Technology | 12.9% |
| 3 | Consumer Discretionary | 10.45% |
| 4 | Financials | 8.48% |
| 5 | Industrials | 7.26% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
VRE
276
DELISTED
Veris Residential
VRE
| $100M | 0.08% |
4,336,700
-608,625
| -12% | -$13.2M |
|
277
Expedia Group
EXPE
$38.5B
| $100M | 0.08% |
926,265
-1,230,700
| -57% | -$144M |
|
278
GeoPark
GPRK
$604M
| $99.7M | 0.08% |
4,527,132
+58,930
| +1% | +$1.12M |
|
279
Highwoods Properties
HIW
$3.4B
| $99.4M | 0.08% |
2,033,183
-443,417
| -18% | -$20.5M |
|
280
TJX Companies
TJX
$172B
| $99.2M | 0.08% |
1,625,300
+940,600
| +137% | +$55.6M |
|
281
Old Republic International
ORI
$10.2B
| $98.9M | 0.08% |
4,423,020
-1,555,573
| -26% | -$35.4M |
|
282
Sinclair Inc
SBGI
$989M
| $98.9M | 0.08% |
2,966,199
-1,130,628
| -28% | -$42.1M |
|
|
RPAI
283
DELISTED
RETAIL PROPERTIES OF AMERICA, INC.
RPAI
| $98.5M | 0.08% |
7,353,321
+284,969
| +4% | +$3.83M |
|
|
SJR
284
DELISTED
Shaw Communications Inc.
SJR
| $98.1M | 0.08% |
4,833,644
+98,244
| +2% | +$1.98M |
|
285
Manulife Financial
MFC
$72.7B
| $97.8M | 0.08% |
4,817,412
-1,526,502
| -24% | -$29.2M |
|
|
X
286
DELISTED
US Steel
X
| $97.4M | 0.07% |
8,534,700
+1,449,400
| +20% | +$18M |
|
287
Coca-Cola Femsa
KOF
$23B
| $97.1M | 0.07% |
1,602,100
+107,000
| +7% | +$6.29M |
|
288
CVR Energy
CVI
$3.42B
| $97M | 0.07% |
2,399,379
+294,610
| +14% | +$12.9M |
|
289
Trip.com Group
TCOM
$29.1B
| $96.4M | 0.07% |
2,872,879
+742,988
| +35% | +$23.9M |
|
290
HP
HPQ
$26.6B
| $95.7M | 0.07% |
4,654,894
+3,318,494
| +248% | +$62.9M |
|
|
SWCH
291
DELISTED
Switch, Inc. Class A Common Stock
SWCH
| $95.5M | 0.07% |
6,444,555
+930,388
| +17% | +$14.1M |
|
292
WSFS Financial
WSFS
$4.14B
| $95.1M | 0.07% |
2,162,631
-170,202
| -7% | -$7.44M |
|
293
Liberty Global Class A
LBTYA
$3.48B
| $94.9M | 0.07% |
4,175,196
+1,579,664
| +61% | +$37.2M |
|
294
Sony
SONY
$138B
| $94.5M | 0.07% |
6,949,000
-7,487,000
| -52% | -$93.3M |
|
295
Corcept Therapeutics
CORT
$12.1B
| $94M | 0.07% |
7,768,214
+1,244,005
| +19% | +$17.3M |
|
|
SPR
296
DELISTED
Spirit AeroSystems
SPR
| $93.9M | 0.07% |
1,287,799
+668,599
| +108% | +$55.1M |
|
297
Gentex
GNTX
$5.04B
| $93.7M | 0.07% |
3,233,835
+175,402
| +6% | +$4.94M |
|
298
Perdoceo Education
PRDO
$1.95B
| $93.5M | 0.07% |
5,086,095
+287,532
| +6% | +$4.68M |
|
299
Lockheed Martin
LMT
$138B
| $93.2M | 0.07% |
239,300
+195,309
| +444% | +$74.9M |
|
|
MZTI
300
The Marzetti Company
MZTI
$3.15B
| $93.1M | 0.07% |
581,362
-57,000
| -9% | -$8.58M |
|
Similar funds
Jim Simons's Q4 2019 Portfolio in Review
As of Q4 2019, Jim Simons held 3,913 positions worth $130B, up 10% from $118B the previous quarter. Its ten largest holdings account for 13% of the portfolio.
Jim Simons's Q4 2019 filing shows 518 new, 1,836 increased, 1,085 reduced and 443 closed positions. Its largest new stake was Amazon: 6,745,100 shares worth $623M. The largest sale was Celgene Corp, an estimated $1.54B.
By sector, the portfolio is most concentrated in Healthcare at 21% of assets, up from 19% a quarter earlier, followed by Technology and Consumer Discretionary.
- Jim Simons's largest Q4 2019 buy was Amazon: 6,745,100 shares worth $623M.
- Jim Simons added most to Bristol-Myers Squibb in Q4 2019, an estimated $1.57B increase.
- Jim Simons's biggest Q4 2019 reduction was Johnson & Johnson, cutting an estimated $561M.
- Jim Simons fully exited Celgene Corp in Q4 2019, selling an estimated $1.54B.
- Jim Simons's ten largest holdings make up 13% of its $130B portfolio in Q4 2019.
- Jim Simons opened 518 new positions and closed 443 in Q4 2019.
- Jim Simons's portfolio value rose 10% quarter-over-quarter to $130B.
Based on Renaissance Technologies's 13F filing for Q4 2019, filed 13 Feb 2020.